PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

FDA advisory committee to review Amylyx ALS drug again

The FDA will reconvene its Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) to discuss Amylyx’s ALS drug candidate later this year, the company announced this week.

The advisory board had previously met in March to discuss the New Drug Application (NDA) for AMX0035. After the FDA determined that additional analyses from clinical studies constitute major amendments to the application, the drug will be evaluated again for the treatment of amyotrophic lateral sclerosis in September of this year.

AMX0035 is an oral-fixed dose medication currently approved with conditions under the brand name Albrioza to treat ALS in Canada. The drug works by combining sodium phenylbutyrate and taurursodiol which are believed to reduce neuronal cell death by mitigating stress and dysfunction of crucial organelles, or the cell’s organs.

“We are pleased that the members of the advisory panel will review additional analyses from our clinical studies, including recently published analyses, supporting the previously reported functional and overall survival benefit for AMX0035,” said Tammy Sarnelli, Global Head of Regulatory Affairs of Amylyx. “As we have heard from the ALS community, there is a crucial need for new and effective treatments in ALS, and our team will continue to work around the clock to advance treatments for ALS in the U.S.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026